Next-generation ‘anti-cancer weapons’ to be developed in innovative partnership between Randox and Transgene
Next-generation ‘anti-cancer weapons’ to be developed in innovative partnership between Randox and Transgene
Randox Laboratories has today announced an innovative European partnership with French biotech company Transgene, which aims to develop a game-changing therapy for cancer treatments.
It involves cutting-edge technology and ‘anti-cancer weapons’ in the form of oncolytic viruses which directly target and destroy the cancer cells, and also deliver antibodies in the tumour microenvironment to further attack the rest of the tumour. This has clear advantages over traditional treatments such as radiotherapy and chemotherapy which as well as targeting cancer cells, can affect healthy cells.
In addition, if successful, this therapy will address the efficacy challenges faced by either Oncolytic viruses or Check-point inhibitors’ neutralization used independently, as their combination is expected to trigger a sustained anti-tumoural immune response from the patient.
The partnership will bring together Randox’s unique collection of therapeutic single domain antibodies (sdABs), which are on the front line in the fight against cancer, and Transgene’s next-generation viral platform Invir.IO™.
Commenting on the agreement, Dr. Peter FitzGerald, Managing Director and Founder of Randox Laboratories, said:
“This collaboration will enable ground-breaking innovation and research to be carried out in a critical area of human health. The work we will be doing in the field of cancer treatment has an enormous potential benefit for patients through the delivery of more effective treatments. We are looking forward to working with Transgene to generate oncolytic viruses that will be able to deliver single and multiple payloads directly into the tumour, enhancing their efficacy. This partnership will allow us to better leverage our SdAb capabilities and immuno-oncology expertise, and add to our strategic collaborations across the world.”
Eric Quéméneur, PhD, Executive VP and VP Research & Development of Transgene, said:
“We are delighted to collaborate with Randox. Its library of SdAbs against major targets in immuno-oncology provides an excellent opportunity to demonstrate the high potential of our Invir.IO™ platform. We look forward to working with Randox and to generating novel product candidates which combine the merits of oncolytic virotherapy and local delivery of therapeutic payloads. We believe such targeted expression of therapeutic agents including immune checkpoint inhibitors will better potentiate the tumour microenvironment and paves the way for the development of a broad range of innovative cancer treatments.”
For further information about Randox’s collaboration with Transgene, please visit our Randox Biosciences website. Click here.
If you have any additional questions please contact Randox PR by phoning 028 9442 2413 or emailing RandoxPR@randox.com
Archives
- June 2022
- May 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- July 2014
- June 2014